CANDEL THERAPEUTICS, INC. Line of Credit Facility, Maximum Borrowing Capacity
CANDEL THERAPEUTICS, INC. (CADL) had Line of Credit Facility, Maximum Borrowing Capacity of $5.00 million as of 2022-12-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2024-11-14
- 2022-12-30: Line of Credit Facility, Maximum Borrowing Capacity $5.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2022-12-30 | $5.00M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |